Search
Eculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions. … Eculizumab is a monoclonal antibody that targets complement protein C5.
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768] … [L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity.
International brands: Ea TenButabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawn[A19735] Its short duration of action gives butabarbital a high abuse potential, comparable to [secobarbital].[A201977,A201980] Butabarbital was granted FDA approval on 5 June 1939.[L13613] … Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Compounds used in a research, industrial, or household settingNebivolol
go.drugbank.com/drugs/DB04861ApprovedInvestigationalNebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. … [A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Mixtures: NEBIVOLOLO E IDROCLOROTIAZIDE DOC GENERICI, NEBIVOLOLO E IDROCLOROTIAZIDE DOC GENERICIProducts: Nebivolol 1A Pharma 5 mg - Tabletten, NEBIVOLOLO DOC GENERICIBamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigationalBamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.
Nadofaragene firadenovec
go.drugbank.com/drugs/DB17381ApprovedInvestigationalNadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). … It is the first gene therapy approved by the FDA for the treatment of bladder cancer.[L44381,L44431] BCG-unresponsive NMIBC has a high recurrence and is notably difficult to treat.
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigational[L64070,L64071] Orca-T was approved by the FDA on June 30, 2026 for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic … [L64070,L64071] It is the first regulatory T cell (Treg)-based immunotherapy approved by the FDA.[L64071]
Alprazolam
go.drugbank.com/drugs/DB00404ApprovedIllicitInvestigational[A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148] … Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.
Synonyms: 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepineProducts: ALPRAZOLAM 1A PHARMA 1MG, ALPRAZOLAM 1A PHARMA 0.5MGAfamelanotide
go.drugbank.com/drugs/DB04931Approved[L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer … Afamelanotide is a first-in-class, synthetic, 13-amino acid peptide analogue of the endogenous alpha melanocyte-stimulating hormone (α-MSH).
Categories: Compounds used in a research, industrial, or household setting